Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects With Episodic Migraine

NCT05028569 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05028569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05028569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects With Episodic Migraine
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Terminated
Start date
November 5, 2021
Completion date
November 6, 2024
Enrollment
775 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

episodic migraine